Fredmann et al.1919. Freedman MS, Comi G, De Stefano N, Barkhof F, Polman CH, Uitdehaag BM et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord. 2014;3(2):147-55. doi:10.1016/j.msard.2013.07.001 https://doi.org/10.1016/j.msard.2013.07....
|
Sistematic review |
2013 |
CIS |
IFN 1A SC, IFN 1A IM, IFN 1B. GA |
Clinical trials |
Start treatment |
Castro-Borrero et al.2222. Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disorder. 2012;5(4):205-20. doi:10.1177/1756285612450936 https://doi.org/10.1177/1756285612450936...
|
Sistematic review |
2012 |
CIS, MSRR |
IFN 1A SC, IFN 1A IM, IFN 1B. GA, MTX, NTZ, FNG |
Pivotal trials |
Efficacy of each drug |
Nicholas et al.2929. Nicholas R, Straube S, Schmidli H, Pfeiffer S, Friede T. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler. 2012;18(9):1290-6. doi:10.1177/1352458511435715 https://doi.org/10.1177/1352458511435715...
|
Sistematic review |
2012 |
MSRR |
Lenercept, CDB, aciclovir, AZA, HIgGIV, MTX, GA, NTZ, RTX |
Clinical trials |
ARR in first and second year follow-up |
Freedmann et al.2020. Freedman MS, Selchen D, Arnold DL, Prat A, Banwell B, Yeung M et al. Treatment optimization in MS: canadian MS Working Group updated recommendations. Can J Neurol Sci. 2013;40(3):307-23. doi:10.1017/S0317167100014244 https://doi.org/10.1017/S031716710001424...
|
Guideline |
2013 |
CIS, MSRR, MSPP, MSSP |
IFN, GA, NTZ, FNG, MTX, Aza, CDB, CFM, RTX, DCZ, OCZ |
Clinical trials |
Relapses, MRI, Cognition, Treatment iniciation, switching, progression |
Dôrr2525. Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17(6):354. doi:10.1007/s11940-015-0354-5 https://doi.org/10.1007/s11940-015-0354-...
|
Guideline |
2015 |
CIS, MSRR |
IFN 1A SC, IFN 1A IM, IFN 1B. GA, TRF, FNG, NTZ, DMF, MTX, ALZ, AZA |
Sumary of reasosn to swith treatment: intra-class and escalating |
Response or tolerability, safety, or adherence issues |
Broadley et al.1515. Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. J Clin Neurosci. 2014;;21(11):1847-56. doi:10.1016/j.jocn.2014.01.018 https://doi.org/10.1016/j.jocn.2014.01.0...
|
Revision and guideline |
2015 |
CIS, MSRR, MSPP, MSSP |
TRF, DMF, ALZ, LQN, DCZ, RTX, AHSCT |
Clinical trials |
ARR, Relapses, disability, new gad lesions, new T2 lesions, brain atrophy |
Gajofatto-Benedetti et al.11. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases. 2015;3(7):545-55. doi:10.12998/wjcc.v3.i7.545 https://doi.org/10.12998/wjcc.v3.i7.545...
|
Revision |
2015 |
CIS, MSRR |
IFN, GA, DMF, TRF, NTZ, FNG, ALZ, MTX, Pegy-IFN, AZA |
Clinical trials |
ARR reduction, tolerability and safety issues |
La Mantia et al.2323. La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F et al. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev. 2014;7:CD009333. doi:10.1002/14651858.CD009333.pub2 https://doi.org/10.1002/14651858.CD00933...
|
Systematic review |
2014 |
CIS, MSRR, MSPP, MSSP |
IFN 1A SC, IFN 1A IM, IFN 1B. GA |
Clinical trials |
Efficacy on relapses, MRI |
Fillippini et al.2626. Filippini G, Del Giovane C, Vacchi L, D'Amico R, Di Pietrantonj C, Beecher D. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochran Datab Syst Rev. 2013;6:CD008933˙. doi:10.1002/14651858.CD008933.pub2 https://doi.org/10.1002/14651858.CD00893...
|
Systematic review |
2014 |
MSRR, MSSP, MSPR |
IFN 1A SC, IFN 1A IM, IFN 1B. GA, NTZ, CFX, AZA, MTT, HIgGIV |
Clinical trials |
Relapses at 24 months of follow-up |
Tulmann et al.2727. Tullman MJ. A review of current and emerging therapeutic strategies in multiple sclerosis. Am J Manag Care. 2013;19(2 Suppl):S21-7.
|
Review |
2014 |
MSRR, MSSP |
IFN 1A SC, IFN 1A IM, IFN 1B. GA, TRF, FNG, NTZ, DMF, MTX, ALZ, DCZ OCZ, LQN |
Clinical trials and reviews |
Efficacy and adverse events |
Wingerchuck et al.2424. Wingerchuk DM, Carter JL Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225-40. doi:10.1016/j.mayocp.2013.11.002 https://doi.org/10.1016/j.mayocp.2013.11...
|
Review |
2015 |
MSRR |
IFN 1A SC, IFN 1A IM, IFN 1B. GA, TRF, FNG, NTZ, DMF, ALZ |
Clinical trials and systematic reviews |
Risk-benefit profiles, monotherapy, escalating and induction therapies |
Damal et al.3030. Damal K, Stoker E, Foley JF. Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action. Biologics. 2013;7:247-58. doi:10.2147/BTT.S53007 https://doi.org/10.2147/BTT.S53007...
|
Review |
2013 |
MSRR |
IFN 1A SC, IFN 1A IM, IFN 1B. GA, NTZ, FNG, TRF, DMF |
Clinical trials |
Mecanism of action and safety |
Weber et al.3131. Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J et al. Current treatment strategies for multiple sclerosis: efficacy versus neurological adverse effects. Curr Pharm Des. 2012;18(2):209-19. doi:10.2174/138161212799040501 https://doi.org/10.2174/1381612127990405...
|
Review |
2012 |
CIS, MSRR, MSPP, MSSP |
IFN, GA TRF, MTX, CDB, NTZ, LQN, RTX |
Clinical trials |
Risk benefit profiles |